Archives

The subscription price for warrants of series TO 3 has been set at SEK 3.78 per share

PHI announces that the subscription price for warrants of series TO 3 has been set at SEK 3.78 per share.
PHI_progress-1024x576-1

BioStock: PHI´s CEO comments on latest advancements

BioStock reached out to PHI´s CEO, Patrik Eschricht, to learn more about the visions moving forward.
Banner image showing gloved hand holding a cell flask.

Interim Report 3 2022/23

Sales have continued to grow, with significantly higher cost efficiency. As a result, rolling 12-month sales gained to its highest level ever.

Clarification Regarding Potential Collaborations

Thi information is provided to mitigate any misinterpretation of the information unintentionally made publicly after a PHI presentation at a CERN Knowledge Transfer Seminar held on March 27, 2023.

Notice that Interim Report 3 2022/23 will be published already on March 28, 2023

PHI changes the date for publication of Interim Report 3 2022/23 to March 28, 2023.
Artistic image of molecularly imprinted polymers (MIP).

PHI creates a subsidiary for the anticipated EU patent concerning synthetic antibodies

PHI has decided to create a dedicated subsidiary to house the synthetic antibody patent family and facilitate its business potential.
KT-seminar-The_Promise_of_Regenerqtion_Medicine_and_AI-Fb_bannernew

CERN seminar: The Promise of Regenerative Medicine and AI

During this seminar, Peter Egelberg, Founder of PHI, will present the work carried out by PHI in the development of time-lapse cytometry instrumentation and software.
springer-book-chaper_web

Technological developments in the rapidly evolving field of live-cell microscopy

Discover more about the developments in live-cell microscopy and how the HoloMonitor® technology is a gentle time-lapse imaging method for non-invasive, long-term and quantitative analysis of living cells.
Swiss-based Altium major investor BioStock

BioStock: PHI catches eye of major investor

BioStock contacted Altium’s CEO Goran Dubravcic to learn more about their incentives to invest in PHI.

Swiss-based Altium acquires major stake in PHI

PHI announces that Altium S.A. recently acquired Formue Nord’s entire holdings in PHI of 2 416 679 shares and 1 491 362 TO 3 warrants and committed to exercise the obtained warrants.
1121314151638